Compare Invesco DB Agriculture Fund (DBA) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs Incyte Corporation — how do they compare? Invesco DB Agriculture Fund trades at $28.36 (market cap $1.32B), while Incyte Corporation trades at $113.16 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 17.3× Invesco DB Agriculture Fund's market cap, and Invesco DB Agriculture Fund is more actively traded (771,657 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and Incyte Corporation for 33 Days on average.
| DBA | INCY | |
|---|---|---|
Market Cap | $1.32B | $22.85B |
Volume | 771,657 | 1,927,029 |
52-Week High | $29.49 | $129.93 |
52-Week Low | $25.44 | $83.80 |
Typical Hold Time | 24 Days | 33 Days |
Sector | — | Health |
Enterprise Value | — | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.295, down 0.68% today, with a bearish technical signal from moving averages but neutral oscillators. The ETF has delivered strong 12.4% YTD returns, outperforming the S&P 500 in recent months according to Zacks Investment Research (2026-07-30). Recent news highlights agricultural ETF strength driven by weather risks and geopolitical tensions, though the fund carries a relatively high 0.85% expense ratio.
The agricultural commodities exposure positions DBA for potential upside from supply chain disruptions and global demand, but investors face volatility risks from commodity price swings and geopolitical uncertainty. Analyst sentiment remains mixed with Seeking Alpha maintaining a Hold rating (2026-09-22) while noting bullish long-term trends since 2020.
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
